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ABSTRACT 
Aim: To deliver antibacterial therapy in an efficacious way, film dosage form has been proposed for drug delivery in vagina which 
can overcome bioavailability issues of poorly water soluble drugs. The present research work is aimed to explore the application of 
mixed solvency concept to increase solubility of poorly water soluble drug, metronidazole. Materials and Methods: Metronidazole, 
a slightly soluble drug in water was tried to be solubilized by employing the combination of solubilizers like niacinamide, sodium 
benzoate, sodium caprylate, caffeine and urea to endeavour its fast dissolving film formulations. The procured sample of drug was 
characterized by UV, IR and DSC studies. The formulations were evaluated for various properties of film such as thickness, folding 
endurance, surface pH, disintegration time and thin layer chromatography. Stability studies of vaginal films of metronidazole were 
performed for ten weeks at room temperature, and refrigerated conditions. Results and Discussion: It was found that 97.54% and 
97.58% of drug was remaining after stability study at respective temperatures in batch F1 and 98.53% and 96.57% in batch 
F4.Conclusion: It was concluded that the approach of mixed solvency concept is novel, safe, cost-effective and user friendly. It also 
eliminates the problem of toxicity associated with high concentration of water-soluble solubilizers. So, it may be employed in dosage 
form development of drugs with poor solubility to overcome bioavailability issues. 
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INTRODUCTION 
The female genital tract consists of cervix and vagina. The 
vagina is extremely flexible, bent canal that is 
approximately 15 cm long in which posterior wall is larger 
than frontal wall because of presence of cervical portion of 
genital tract which is further connected to vestibule. A 
healthy reproductive woman has an acidic vaginal pH. 
There is a natural balance of aerobic and anaerobic 
microbes in vagina.1 The vagina consists of numerous 
microbes that exist in equilibrium, and their presence is 
influenced by various factors such as pregnancy, 
menstruation, hygiene and infection.  Microbes include 
bacteria, yeast and viruses, in which the vagina is 
dominated by Lactobacillus species. Lactobacillus helps to 
prevent such growth of unwanted harmful microbes by 
various mechanisms such as stimulating the immune 
system, maintaining the vaginal pH, production of 
antimicrobial substance such as hydrogen peroxide that 
acts against pathogens and further competing with other 
microbes for nutrients. The reduction in lactobacilli results 
in change in pH of vagina which can lead to other bacterial 
infections such as development of bacterial vaginosis.1,2 
Bacterial vaginosis (BV) occurs as most widely recognized 
vaginal disorder affecting prolific, premenopausal and 
pregnant ladies, with a frequency rate extending from 5% 
to 50 %. BV is depicted by an excess of strict or facultative 
anaerobic microbes and a decrease of lactobacilli 
especially those involved in hydrogen peroxide production. 
Female with BV normally account for vaginal 
inconvenience.3 The symptoms of BV include: 1) an 
increase in fluid discharge from vagina that has common 
"fishy" smell. 2) The colour of discharge is usually milky 
white or gray. 3) Burning sensation and itching while 
urination.4 Diagnosis test include: The presence of clue 
cells (20% of cells as clue cells specify the positivity of 
test), Vaginal discharge (milky white or gray discharge), 
Whiff test (Fishy odour noted after addition of 10% of 
potassium hydroxide) OSOM BV Blue test (based on 
detection of elevated activity of sialidase within the vaginal 
fluid,  blue or green colour indicates that the sample is 
positive for BV).5 Its treatment include oral or vaginal 
antimicrobials such as metronidazole or clindamycin, and 
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probiotics. But conventional dosage forms have certain 
limitations such as lower bioavailability (oral 
formulations), leakage, and inappropriate drug release, 
prolong duration of action (vaginal formulations). These 
limitations are overcome by advanced topical drug 
delivery system such as vaginal film, which is a type of 
polymeric drug delivery system that could be applied 
without using an applicator.6 Vaginal films are designed to 
get rapid dispersion or dissolution of API that come in 
contact with vaginal fluid forming a smooth, viscous, and 
bio-adhesive gel. As vaginal fluid have some water content 
so it favours absorption of drugs having certain solubility 
in water. But for drugs having poor solubility, formulation 
strategies has to be applied to enhance the solubility.7-13 To 
enhance the solubility of the drug, there are several 
methods available, such as changing the pH, using 
cosolvents, using dielectric solvents, using surface active 
agents, complexation, hydrotropic solubilisation, mixed 
hydrotropy and mixed solvency. Mixed solvency concept 
plays an important role to enhance the solubility. 
Mixed Solvency Concept 
As per the mixed solvency concept proposed by 
Maheshwari R.K., each and every substance present in the 
universe has got solubilizing property i.e. all the liquids, 
gases and solids possess solubilizing power. As per his 
statement, each substance is solubilizer. A concentrated 
aqueous solution containing various water soluble 
substances may act as good solvent for poorly water 
soluble drugs.14 By combining various excipients, additive 
and synergistic solvent actions are expected which has 
advantage of reducing the toxicities. For a desired 
solubility enhancement, a single solubilizer may prove 
toxic for human being but the combination of different 
excipients in safe smaller concentrations solves the 
problem of toxicity for same desired solubility of drug.15-30 
In present research work mixed solvency concept has been 
employed to formulate vaginal film of poorly water soluble 
drug, metronidazole. 
2.0 MATERIALS AND METHODS 
2.1 Materials: Metronidazole was obtained as a gift 
sample from Schon pharmaceutical Limited, Indore. 
2.2 Estimation of metronidazole: 
2.2.1 UV spectropholometric analysis of metronidazole 
using 0.1 N HCl 
A solution of 10µg/ml of metronidazole in 0.1 N HCl was 
scanned between 200 to 400 nm on a double beam 
UV/Visible spectrophotometer (Shimadzu 1700). The UV 
spectrum of metronidazole drug sample is shown in figure 
1. 
2.2.2 IR analysis of drug sample: 
Metronidazole drug powder was compressed into a pellet 
along with KBr (KBr pellet technique) using Shimadzu 
hydraulic press. The FTIR spectrum of drug was recorded 
in the wave number region of 450-4000 cm-1 on a FTIR 
spectrophotometer (Shimadzu 8300) and presented in 
figure 2. 
2.2.3 DSC analysis of drug sample: 
The DSC study was performed on a Pyris 6 DSC (Jade DSC) 
differential scanning calorimeter with thermal analyzer. 
Accurately weighed samples (about 3 mg of samples) were 
placed in a sealed aluminum pan, before heating under 
nitrogen flow (20 ml/min) at a scanning rate of 20°C per 
min from 25 to 350° C. An empty aluminum pan was used 
as reference. The DSC spectrum of metronidazole drug 
sample is shown in figure 3. 
2.3 Determination of solubility of metronidazole in 
different solvent medium 
Solubility studies in different solvent mediums were carried 
out by adding an excess amount of drug metronidazole in 5 ml 
of respective medium and keeping the screw capped tubes 
containing these solutions, on a mechanical shaker at room 
temperature for 12 hrs, so that equilibrium solubility can be 
achieved and solutions were allowed to equilibrate for 24 
hrs undisturbed. Then, the solutions were filtered through 
Whatman grade 41 filter. One ml of the filtrate was suitably 
diluted with the respective medium. The absorbances of the 
solutions were measured at 320 nm on a double beam 
UV/Visible spectrophotometer (Simadzu-1700) against 
respective reagent blanks. The results are recorded in table 2. 
2.4 Study of interference of additives in UV 
spectrophotometric estimation of metronidazole 
For determination of interference of additives in the 
spectrophotometric estimation of metronidazole, the 
absorbances of solution containing drug (20µg/ml) alone 
and solution containing drug (20µg/ml) and excipient 
(2000µg/ml) were recorded against respective reagent 
blank at 320 nm and results are shown in table 3. A UV-
visible recording spectrophotometer (Shimadzu 1700) 
with 1 cm matched silica cells was employed for 
spectrophotometric determinations. 
2.5 Formulation development of vaginal film: 
2.5.1 Solubilizer selection 
For the preparation of different blends of solubilizers (% 
w/v), niacinamide, sodium citrate, caffeine, HP beta 
cyclodextrin, PVP K 25 (film forming polymer), PEG 4000, 
propylene glycol, PEG 200, PEG 400, and glycerine were 
used. Total solute concentration was varied up to 40% w/v 
concentration and the % solubility of drug (metronidazole) 
was calculated. To decrease the individual concentration of 
solubilizers as well as individual toxicity of solubilizers, 
combinations of solubilizers in blend were used to increase 
the solubility of drug in various ratios. Solubility studies in 
different aqueous systems of solubilizers were carried out 
by equilibrium solubility method. The results of solubility 
studies are shown in table 4. 
2.5.2 Polymer selection 
For the development of fast dissolving film, HPMC E5, 
HPMC E50, sodium alginate, PVA, gelatine, CMC were used 
as film forming polymer (table 5). Blend composition 
NM:SB:UR:SC =15:10:10:5 (B1) and  NM:SB:UR:CF 
=15:10:10:5 (B2) were selected for film formulation. (NM-
Niacinamide, SC-Sodium caprylate, UR-Urea, SB-Sodium 
benzoate, CF-Caffeine) 
Procedure for preparation of single film: 
0.8ml blend was taken in a 5ml vial to which accurately 
weighed 40mg drug was added and covered with the 
closure then the vial was shaken well to dissolve the drug. 
Then 0.2 ml plasticizer (glycerine) and 200mg polymer 
was added to above solution and it was mixed properly 
using vortex mixer. Then, the film solution was kept 
undisturbed for 5 hours so as to remove the entrapped air 
bubble and for proper swelling of the polymer. Then the 
film solution was poured over a glass petridish and kept 
for drying at room temperature for 24 hrs. 
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2.5.2.1 Evaluation of casted polymeric film 
a) Folding endurance 
Folding endurance was determined by repeatedly folding 
the film at the same position until it breaks. The number of 
times the films can be folded without breaking is termed as 
the folding endurance value. 
b) Thickness 
The thickness of film was determined by the use of 
micrometer (Digimatic micrometer, Mitutoyo, Tokyo, 
Japan) at five locations (centre and four corners) and mean 
thickness was calculated. 
2.8.2.2  Optimization of polymer concentration 
Three batches of selected polymer (HPMC E-5) having 
different concentrations were prepared, casted and their 
film properties were studied. Results are shown in table 6. 
2.5.3 Selection of plasticizer 
Five batches of HPMC E-5 with different plasticizers (table 
7) having concentration 20% v/v were prepared and 
casted, after proper drying the films were scrapped out 
and their film properties were studied. 
2.5. 3.1 Optimization of plasticizer concentration 
Several batches of HPMC E-5 with different concentration 
range 10%-20% of selected plasticizer glycerine were 
prepared by adjusting the blend concentration according 
to the concentration of selected plasticizer so as to get 
100% v/v film solution. Then, the prepared batches were 
evaluated for film properties (table 8). 
2.5.4 Optimized batch formula 
According to the preliminary studies and studies of 
selection of excipients, 6 batches were optimized. 
  
Table 1: Optimized blend for formulation development 
S.No. Batch code Blend 
(8ml) 
HPMC E5 (polymer) 
concentration 
Glycerine (plasticizer) 
concentration 
Drug used for 10ml 
film solution 
1. F1 B1 15%w/v 20%v/v 500mg 
2. F2 B1 17%w/v 20%v/v 500mg 
3. F3 B1 20%w/v 20%v/v 500mg 
4. F4 B2 15%w/v 20%v/v 500mg 
5. F5 B2 17%w/v 20%v/v 500mg 
6. F6 B2 20%w/v 20%v/v 500mg 
 
2.5.4.1 Method of preparation of fast dissolving film:- 
500 mg metronidazole was accurately weighed and 
dissolved in 8ml of respective solubilizer blend taken in a 
vial of 20ml capacity. Then, 20% v/v glycerine (as 
plasticizer) and respective concentration (15% or 17% or 
20%w/v) of HPMC E-5 (as film forming polymer) were 
added and properly mixed using vortex mixer. The 
preparation was placed undisturbed for 5 hrs (for removal 
of entrapped air bubble and proper swelling of polymer) 
and then 5ml of prepared film solution was pipetted out 
and it was uniformly spread over glass petridishes and 
then kept for drying at room temperature for 24 hrs. After 
proper drying, films were cut into desired calculated 
dimension i.e. 3.5×3.5 cm2 in which 40mg of metronidazole 
was present. At last they were wrapped in aluminium foils 
with sealing plastic bags and stored for further evaluations 
of films. 
2.5.4.2 Evaluation parameters:- 
a) In-vitro release studies  
Release study of metronidazole film containing 40mg drug 
was performed by setting an assembly in which the film 
was placed in the beaker containing 30 ml of simulated 
vaginal fluid on a magnetic stirrer at 50 rpm. Five ml of 
dissolution media was withdrawn at regular intervals and 
fresh media was replaced immediately after withdrawal of 
sample. The sample was filtered and suitably diluted with 
demineralised water and then analysed in U.V. at 320nm 
and absorbance was noted against reagent blank (using 
placebo). Drug release is graphically represented in figure 
4. 
b) Surface pH 
Film was taken and placed in a glass petridish containing 5 
ml of simulated vaginal fluid. After wetting of the film, the 
surface pH of the film was checked by using pH electrode. 
c) Disintegration time 
10ml of demineralised water was placed in a beaker and 
one film was added on the surface of the water and it was 
shaken briskly. The time was measured until the film was 
dissolved completely. 
d)  Thin layer chromatography (TLC) analysis  
TLC analysis was done to check any drug-solubilizer 
interaction (table 10). Acetone was used as solvent for 
preparation of standard solution of drug and test solution 
was prepared in aqueous blend of solubilizers. The mobile 
phase consisted of a mixture of 80 volumes of chloroform, 
10 volumes of diethylamine, 10 volumes of ethanol, and 1 
volume of water.  
e) Stability study of optimized batches F1 and F4: 
Stability study of optimized film formulation was carried 
out for 10 weeks at 2-8°C (refrigerator) and 25°C±2°C 
(room temperature). 
3.0 RESULTS AND DISCUSSION 
3.1 Drug characterization: 
3.1.1 UV spectrophotometric analysis of 
metronidazole:  The UV spectrum of metronidazole drug 
sample was scanned between 200 to 400 nm. λmax of 
metronidazole was found to be 277 nm which is same as 
reported in literature. 
3.1.2 IR analysis of drug sample: The FTIR spectrum of 
drug sample had shown identical peaks as reported in 
reference sample of metronidazole. 
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Figure 1: UV spectrum of metronidazole drug sample in 0.1M HCl 
 
Figure 2: IR spectra of metronidazole 
 
3.1.3 DSC analysis of drug sample: The DSC spectrum of metronidazole was same as reported in literature. 
 
Figure 3: DSC spectrum of metronidazole drug sample 
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3.2 Determination of solubility of metronidazole in different solvent medium: 
Table 2: Solubility data of metronidazole in different solvent medium 
S. No. Solvent systems Solubility (mg/ml) Inference 
1. Demineralized water 9.8 Slightly soluble 
2. Citrate buffer (pH 4.4) 9.3 Slightly soluble 
 
3.3 Study of interference of additives in UV spectrophotometric estimation of metronidazole: Observing the results 
from table 3 of drug-excipients interference study, it was concluded that there is nearly no interference in UV 
spectrophotometric analysis of metronidazole due to excipients. 
Table 3: Drug-excipient interference study 
Drug Excipient Drug conc. 
(µg/ml) 
Solubilizer 
conc. (µg/ml) 
Lambda max 
(nm) 
Absorbance 
Metronidazole - 20 - 320 1.037 
Metronidazole Sodium benzoate 20 2000 320 1.045 
Metronidazole Niacinamide 20 2000 320 1.041 
Metronidazole Urea 20 2000 320 1.043 
Metronidazole Sodium caprylate 20 2000 320 1.040 
Metronidazole Caffeine 20 2000 320 1.038 
Metronidazole PVP K 25 20 2000 320 1.041 
 
3.4 Formulation development of vaginal film: 
3.4.1 Solubilizer selection 
Table 4: Solubility of drug in aqueous solutions containing various solubilizers 
S.No. Aqueous blend of 
solubilizers 
Concentration 
(%w/v) 
Solubility 
(mg/ml) 
Solubility 
(%w/v) 
Solubility 
enhancement ratio 
1 DM water --- 9.80 0.98 --- 
2 PG 15 12.47 1.25 1.27 
3 Glycerine 15 11.82 1.18 1.20 
4 PEG 200 15 10.00 1.00 1.02 
5 PEG 400 15 10. 12 1.01 1.03 
6 PVP K 25 10 11.47 1.15 1.17 
7 Urea 20 17.61 1.76 1.79 
8 Sodium benzoate 20 27.94 2.79 2.48 
9 Niacinamide 20 30.88 3.09 3.15 
10 Sodium caprylate 20 15.14 1.51 1.54 
11 PG:NM 20:20 34.07 3.41 3.47 
12 PG:SB 20:20 26.19 2.62 2.67 
33 PG:SC 20:20 19.11 1.91 1.94 
14 GLY:NM 20:20 31.09 3.11 3.17 
15 GLY:SC 20:20 16.66 1.67 1.70 
16 GLY:SB 20:20 25.94 2.59 2.64 
17 NM:SB 20:20 53.64 5.36 5.46 
18 UR:SB 20:20 48.15 4.82 4.91 
19 UR:NM 20:20 44.62 4.46 4.55 
20 NM:SB:UR 20:10:10 36.74 3.67 3.74 
21 SB:SC:NM 10:20:10 27.49 2.75 2.80 
22 NM:SB:SC 10:20:10 37.96 3.80 3.87 
24 NM:SB:UR:PEG 4000 15:10:10:5 41.01         4.10 4.18 
25 NM:SB:UR:HBC 15:10:10:5 39.25 3.93 4.01 
26 NM:SB:UR:CF 15:10:10:5 52.38 5.24 5.34 
27 NM:SB:UR:PVPK25 15:10:10:5 40.30 4.03 4.11 
28 NM:SB:UR:SC 15:10:10:5 50.94 5.09 5.19 
 
NM-Niacinamide, SC-Sodium caprylate, UR-Urea, SB-Sodium benzoate, CF-Caffeine, HBC-Hβ cyclodextrin. 
3.4.2 Polymer selection: HPMC E-5 was taken in further studies because it gave better film properties (table 5) compared 
to other polymers used to prepare the film.  
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Table 5: Evaluation of film properties 
S.No. Polymer Physical appearance of film Folding endurance 
B1 B2 B1 B2 
1 HPMC-E5 Transparent, flexible Hazy, flexible 167 183 
2 HPMC-E50 Transparent Translucent 103 118 
3 Sodium alginate Opaque, Powdered on 
scrapping 
Opaque, cracked --- --- 
4 PVA Transparent opaque 55 73 
5 Gelatin Yellowish, translucent, 
cracked 
Yellowish, hazy, hard,  brittle ---- --- 
6 CMC Opaque, hard, non- 
foldable 
Opaque, brittle --- --- 
 
3.4.2.1 Optimization of polymer concentration: On the basis of selection factors (table 6), 20% w/v concentration of 
HPMC E-5 was selected and was used in further formulation development studies. 
Table 6: Properties of different concentrations of HPMC E-5 
S.No Property of 
film 
Polymer 
HPMC E5 (20%) HPMC E5 (25%) HPMC E5(30%) 
B1 B2 B1 B2 B1 B2 
1. Pourability Easy  Easy  Difficult Difficult Non 
pourable 
Non 
pourable 
2. Appearance Transparent Hazy Transparent Hazy --- --- 
3. Thickness 0.05 mm 0.07 mm 0.09 mm 0.10 mm --- --- 
 
3.4.3 Selection of plasticizer: On the basis of film properties and effect of plasticizer in polymeric film (table 7), glycerine 
was selected, it shows better results compared to other plasticizers. 
Table 7: Effect of different plasticizers in polymeric casted film 
S.No. Plasticizer 
   (20%v/v) 
Polymer 
(20%w/v) 
Appearance Folding endurance 
B1 B2 B1 B2 
1 Glycerine HPMC E5 Tranparent, flexible, easily 
peelable 
Translucent, flexible, 
easily peelable 
170 182 
2 Propylene  glycol HPMC E5 Translucent, less flexible  Hazy, less flexible 80 103 
3 PEG 200 HPMC E5 Hazy, less flexible Hazy, less flexible 73 94 
4 PEG 400 HPMC E5 White, non flexible White, non flexible --- --- 
 
3.4.3.1 Optimization of plasticizer concentration: On the basis of film properties (table 8), 20% v/v concentration of 
glycerine was optimized and used in further studies of formulation development. 
Table 8: Effect of different concentrations of selected plasticizers in properties of polymeric film 
S.No. Plasticizer 
concentration 
(glycerine) 
Appearance Thickness 
(mm) 
Folding 
endurance 
B1 B2 B1 B2 B1 B2 
1. 10%v/v Hazy, hard, brittle White, hard, brittle 0.04 0.03 --- --- 
2. 15%v/v Translucent, flexible Hazy, flexible 0.04 0.05 70 96 
3. 20%v/v Transparent, highly flexible Translucent, highly flexible 0.05  mm 0.07 mm 175 186 
 
3.5 Evaluations of optimized batches – On the basis of evaluation parameters (table 9) of different batches of films, batch 
F1 and batch F4 were found to be more appropriate and gave better results as compared to other batches.  
Table 9: Evaluation of formulated film batches 
S.No. Batch Thickness (mm) 
(average of 5 different positions) 
Folding endurance 
(number) 
pH Disintigration 
time (sec) 
1. F1 0.06 173 4.67 57 
2. F2 0.08 103 4.73 70 
3. F3 0.12 68 4.80 82 
4. F4 0.08 186 4.69 60 
5. F5 0.09 125 4.76 76 
6. F6 0.11 34 4.82 89 
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3.5.1 Thin layer chromatography (TLC) analysis: 
Table 10: TLC analysis of pure metronidazole and in blend of solubilizers 
S.No. Mobile phase Rf value Inference 
Standard 
solution 
B1 B2 
1. Chloroform:diethylamine: 
ethanol:water = 80:10:10:1 
0.921 0.923 0.921 No significant change in Rf  value 
hence no interaction between drug 
and solubilizers 
 
3.5.2 In-vitro release studies: The % cumulative drug release of optimized batches F1 and F4 in simulated vaginal fluid in 
60 minutes were found to be 99.82% and 99.77%,  respectively (table 11). 
Table 11: In-vitro drug dissolution profile of fast dissolving metronidazole film in simulated vaginal fluid. 
S.No. Time (min.) % Cumulative drug release 
F1 F2 F3 F4 F5 F6 
1. 2 46.73 23.78 21.40 41.71 34.28 30.46 
2. 5 67.79 44.63 34.81 47.81 48.82 49.60 
3. 10 83.81 62.28 47.05 66.76 73.81 63.56 
4. 15 94.36 69.27 52.03 81.55 85.81 91.91 
5. 30 98.72 79.67 65.36 86.64 93.47 91.68 
6. 45 99.61 91.68 73.71 94.77 94.56 84.60 
7. 60 99.82 96.50 91.16 99.77 88.71 84.40 
 
 
Figure 4: Graphical representation of % cumulative drug release in simulated vaginal fluid 
 
3.5.3 Stability study of optimized batches F1 and F4: 
The developed film of metronidazole was found to be 
stable for ten weeks at room temperature as well as 
refrigerated condition. It was found that 97.54% and 
97.58% of drug was remaining after stability study at 
respective temperatures in batch F1 and 98.53% and 
96.57% in batch F4. 
4.0 CONCLUSION 
In the present study, metronidazole, a slightly soluble drug 
in water was tried to be solubilized by employing the 
combination of physiologically compatible solubilizers to 
endeavour its fast dissolving formulations. Amongst all the 
batches, F1 and F4 batches of prepared fast dissolving 
films showed better in-vitro dissolution profile, 
disintegration time and were selected for stability studies. 
It was found to be stable for 10 weeks. The loading of drug 
got increased and hence the area of film was reduced. 
From all the above studies, it was concluded that the 
approach of mixed solvency concept is novel, safe, cost-
effective and user friendly. It also eliminates the problem 
of toxicity associated with high concentration of water-
soluble solubilizers. So, it may be employed in dosage form 
development of drugs where fast onset of action is 
required.
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